Potential Prognostic Protein Biomarkers in Tears From Noninfectious Uveitis Patients Under Biologic Treatment as a Prelude to Personalized Medicine
Investigative Ophthalmology & Visual Science · 2024-11-14 · 65 (13) · 29
DOI: 10.1167/iovs.65.13.29 ↗At a glance
Beobachtungsstudie in Investigative Ophthalmology & Visual Science, published on 2024-11-14. Written by Lorena Rodríguez-Martínez and 6 co-authors. Institution: FarmaCHUSLab Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Major MEDLINE topics: Tears, Biomarkers, Adalimumab, Uveitis. Cited 6 times so far (Crossref); 68 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
Adalimumab (ADA) is a systemic biological treatment option approved for the treatment of noninfectious uveitis (NIU); however, up to 40% of patients do not respond to the drug, either in a primary or secondary manner. Here, we evaluated the proteomic profile of patients with NIU who fail to ADA to identify proteins implicated in intraocular inflammation, as well as potential biomarkers for treatment response and novel therapeutic targets.
Methods
Cross-sectional observational study of patients with NIU under ADA treatment for six or more months. Tears were collected with microcapillary tubes and protein analyzed by data-independent acquisition/sequential window acquisition of all theoretical mass spectra. Differentially expressed proteins (DEPs) were defined based on the fold change between their expression in nonresponders (NR) and responders (R). Protein network and gene ontology analysis were performed. The χ2 test for trend and receiver operating characteristic (ROC) curves were used to evaluate potential biomarkers of treatment response.
Results
Twenty-nine DEPs, 14 upregulated and 15 downregulated, were detected in NR. These proteins were mainly related to enhanced neutrophil effector functions and redox imbalance. ROC analysis identified defensin-1,3 (DEF-1,3), biotinidase, and ATP-binding cassette transporter A1 as potential biomarkers for treatment response.
Conclusions
This is the first study on a clinical cohort of patients with noninfectious uveitis that identifies tear proteins related to neutrophil hyperactivation as drivers of the persistent intraocular inflammation observed in NR to ADA and provides evidence that targeting interleukin 6, Janus kinases, or the complement cascade could be potential alternative therapeutic strategies in these patients. Our results indicate the potential of high-throughput proteomics to provide insights into the underlying pathological mechanisms of persistent intraocular inflammation observed in patients who do not adequately respond to anti-TNF treatment and the value of tear proteomics as a tool for personalized medicine.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- FarmaCHUSLab Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
- Department of Ophthalmology, Bellvitge University Hospital, 08907 Hospitalet de Llobregat, Spain.
- Ophthalmology Department, University Clinical Hospital of Vigo (SERGAS), Vigo, Spain.
- Ophthalmology Department, University Clinical Hospital of Santiago Compostela (SERGAS), Santiago de Compostela, Spain.
- Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), Santiago de Compostela, Spain.
Cite
APA
Rodríguez-Martínez, L., Rodríguez-Fernández, C. A., Rodríguez Lemos, O., de Domingo, B., García Bru, P., Mateos, J., & Fernández-Ferreiro, A. (2024). Potential Prognostic Protein Biomarkers in Tears From Noninfectious Uveitis Patients Under Biologic Treatment as a Prelude to Personalized Medicine. Investigative Ophthalmology & Visual Science, 65(13), 29. https://doi.org/10.1167/iovs.65.13.29
Vancouver
Rodríguez-Martínez L, Rodríguez-Fernández CA, Rodríguez Lemos O, de Domingo B, García Bru P, Mateos J, et al. Potential Prognostic Protein Biomarkers in Tears From Noninfectious Uveitis Patients Under Biologic Treatment as a Prelude to Personalized Medicine. Investigative Ophthalmology & Visual Science. 2024;65(13):29. doi:10.1167/iovs.65.13.29
BibTeX
@article{RodrguezMartnez2024,
author = {Rodríguez-Martínez, Lorena and Rodríguez-Fernández, Carmen Antía and Rodríguez Lemos, Olalla and de Domingo, Begoña and García Bru, Pere and Mateos, Jesús and Fernández-Ferreiro, Anxo},
title = {Potential Prognostic Protein Biomarkers in Tears From Noninfectious Uveitis Patients Under Biologic Treatment as a Prelude to Personalized Medicine},
journal = {Investigative Ophthalmology & Visual Science},
year = {2024},
volume = {65},
number = {13},
pages = {29},
doi = {10.1167/iovs.65.13.29}
}
EUVIMED